BJRD Medical Technology Group announced that it has signed a strategic cooperation agreement with the American company Myomo.Inc on January 21. In the future, Chuangfang will establish a joint venture company in China to manufacture and sell MYOMO’s existing upper limbs. Full range of skeletal stent robots and future products. At the same time, the two parties announced that the joint venture company will jointly set up a research and development team to develop new and upgraded products suitable for the local market.
Myomo is a US listed company that was listed on Nasdaq in June 2017. Myomo focuses on the medical robot market and has developed the MyomoPro series of exoskeleton stent robots, which can help patients repair strokes, spinal cord or nerve injuries (brachial plexus injury or other neuromuscular injuries, etc.), and arm function, amyotrophic lateral sclerosis (ALS) And multiple sclerosis (MS) and other physical disabilities. According to the information on the official website, Myomo has been listed as an applicable device by more than 20 medical institutions in the United States. Currently, more than 600 devices have been used for patient rehabilitation.
BJRD focuses on the field of rehabilitation treatment and currently has two major business segments: rehabilitation medical services and rehabilitation medical equipment production. In terms of rehabilitation medical services, BJRD conducts business in the PPP mode (Public-Private-Partnership) or IOT (Investment-Operation-Transfer) mode, and through cooperation with public medical institutions, it carries out the construction of rehabilitation centers or institutional trusteeship. BJRD has participated in the operation of the Third People's Hospital of Chenzhou City, Beijing Longhua Hospital, Tieling City Hospital of Traditional Chinese Medicine and other medical institutions, and has cooperated with the Third Affiliated Hospital of Peking University to prepare hospitals.
In terms of rehabilitation medical equipment, BJRD has more than 200 types of rehabilitation medical equipment products including orthopedic rehabilitation, neurorehabilitation, rehabilitation evaluation, physical factor therapy and other fields. Its production base is located in the medical industry incubator.
According to statistics, the scale of China's exoskeleton robot market reached 6.2 million yuan in 2017 and exceeded 40 million yuan in 2018. It is foreseeable that with the aging of the population, the improvement of medical standards, and the rapid decline of costs, medical rehabilitation exoskeleton robots may usher in an explosive period in the future.
Major foreign exoskeleton robot companies include Rewalk, Cyberdyne, EksoEkso Bionics, B-Temia, Lockheed Martin, Bionic Power, etc.
At present, China's rehabilitation exoskeleton robot track has emerged many start-up companies, such as Dayi, Fourier Intelligent, Aosha Intelligent, Step Robot, Yuanye Technology, Ruihan Medical, Scream Technology, Jinhe and other companies.